Pub Date : 2022-04-27DOI: 10.1101/2022.04.24.22274237
Tal Brosh-Nissimov, K. Hussein, Y. Wiener‐Well, E. Orenbuch-Harroch, Meital Elbaz, Shelly Lipman-Arens, Y. Maor, Y. Yagel, B. Chazan, M. Hershman-Sarafov, G. Rahav, O. Zimhony, Adi Zaidman Shimshovitz, M. Chowers
Importance: Waning immunity against COVID-19 in parallel with an increased incidence during the Omicron outbreak led the Israeli Ministry of Health to recommend a second booster dose of BNT162b2 (Pfizer) to high-risk individuals. Israel was the first country to recommend this, allowing evaluation of the added protection of a fourth vaccine dose to hospitalized patients with severe diseases. Objective: To assess the effect of a fourth dose for hospitalized patients with severe/critical breakthrough COVID-19. Design: A cohort study of hospitalized adults from 01/15/2022-01/31/2022. Settings: A multi center study of 14 medical centers in Israel. Participants: Hospitalized adult patients with PCR-confirmed severe/critical COVID-19. Excluded were patients lacking data on vaccination status. Exposure: Cases were divided according to the total number of vaccine doses received up to 7 days before diagnosis. Unvaccinated adults and single-dose recipients were grouped into an unvaccinated group. Main Outcome: A composite of mechanical ventilation or in-hospital death was defined as poor outcome. Outcomes were compared between 3- and 4-dose vaccinees. Results: Included were 1,049 patients with severe/critical COVID-19, median age 80 (IQR 69-87), 51% males. Among them, 360 unvaccinated, 34, 172, 386 and 88 were after 1, 2, 3 or 4 doses, respectively. Patients after 3 doses were older, had more males and immunosuppression, but with similar outcomes, 49% vs. 51% compared to unvaccinated patients (p=0.72). Patients after 4 doses were similarly older and immunosuppressed, but had improved outcomes compared to unvaccinated patients, 34% vs. 51% (p<0.01). We proceeded to examine independent predictors for poor outcome in fully-vaccinated patients with either 3 doses given a median of 161 (IQR 147-168) days earlier, or 4 doses given a median of 14 (IQR 10-18) days before diagnoses. Receipt of the fourth dose conferred significant protection: OR 0.51 (95%CI 0.30.87). Conclusion and Relevance: Within a population of hospitalized patients with severe/critical breakthrough COVID-19, a recent fourth dose was associated with significant protection against mechanical ventilation or death, compared to fully-vaccinated single boosted individuals.
{"title":"Hospitalized patients with severe COVID-19 during the Omicron wave in Israel – benefits of a fourth vaccine dose","authors":"Tal Brosh-Nissimov, K. Hussein, Y. Wiener‐Well, E. Orenbuch-Harroch, Meital Elbaz, Shelly Lipman-Arens, Y. Maor, Y. Yagel, B. Chazan, M. Hershman-Sarafov, G. Rahav, O. Zimhony, Adi Zaidman Shimshovitz, M. Chowers","doi":"10.1101/2022.04.24.22274237","DOIUrl":"https://doi.org/10.1101/2022.04.24.22274237","url":null,"abstract":"Importance: Waning immunity against COVID-19 in parallel with an increased incidence during the Omicron outbreak led the Israeli Ministry of Health to recommend a second booster dose of BNT162b2 (Pfizer) to high-risk individuals. Israel was the first country to recommend this, allowing evaluation of the added protection of a fourth vaccine dose to hospitalized patients with severe diseases. Objective: To assess the effect of a fourth dose for hospitalized patients with severe/critical breakthrough COVID-19. Design: A cohort study of hospitalized adults from 01/15/2022-01/31/2022. Settings: A multi center study of 14 medical centers in Israel. Participants: Hospitalized adult patients with PCR-confirmed severe/critical COVID-19. Excluded were patients lacking data on vaccination status. Exposure: Cases were divided according to the total number of vaccine doses received up to 7 days before diagnosis. Unvaccinated adults and single-dose recipients were grouped into an unvaccinated group. Main Outcome: A composite of mechanical ventilation or in-hospital death was defined as poor outcome. Outcomes were compared between 3- and 4-dose vaccinees. Results: Included were 1,049 patients with severe/critical COVID-19, median age 80 (IQR 69-87), 51% males. Among them, 360 unvaccinated, 34, 172, 386 and 88 were after 1, 2, 3 or 4 doses, respectively. Patients after 3 doses were older, had more males and immunosuppression, but with similar outcomes, 49% vs. 51% compared to unvaccinated patients (p=0.72). Patients after 4 doses were similarly older and immunosuppressed, but had improved outcomes compared to unvaccinated patients, 34% vs. 51% (p<0.01). We proceeded to examine independent predictors for poor outcome in fully-vaccinated patients with either 3 doses given a median of 161 (IQR 147-168) days earlier, or 4 doses given a median of 14 (IQR 10-18) days before diagnoses. Receipt of the fourth dose conferred significant protection: OR 0.51 (95%CI 0.30.87). Conclusion and Relevance: Within a population of hospitalized patients with severe/critical breakthrough COVID-19, a recent fourth dose was associated with significant protection against mechanical ventilation or death, compared to fully-vaccinated single boosted individuals.","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90527902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-27DOI: 10.1101/2022.04.23.22274214
S. Qasmieh, M. Robertson, C. Teasdale, S. Kulkarni, D. Nash
In a population-based survey of NYC adults, we assessed positive SARS-CoV-2 tests (including via exclusive at-home testing) and possible cases among untested respondents. An estimated 27.4% (95%CI: 22.8%-32.0%) or 1.8 million adults (95%CI: 1.6-2.1 million) had SARS-CoV-2 infection. SARS-CoV-2 prevalence was high among groups that are more vulnerable to severe SARS-CoV-2 and death, including unvaccinated persons (21.7%, 95%CI 9.6%-33.8%) and those aged 65+ (17.8%, 95%CI 10.2-25.4%). Population-based representative surveys are an important adjunct surveillance tool to standard testing-based SARS-CoV-2 surveillance.
{"title":"Estimating the period prevalence of SARS-CoV-2 infection during the Omicron (BA.1) surge in New York City (NYC), January 1-March 16, 2022","authors":"S. Qasmieh, M. Robertson, C. Teasdale, S. Kulkarni, D. Nash","doi":"10.1101/2022.04.23.22274214","DOIUrl":"https://doi.org/10.1101/2022.04.23.22274214","url":null,"abstract":"In a population-based survey of NYC adults, we assessed positive SARS-CoV-2 tests (including via exclusive at-home testing) and possible cases among untested respondents. An estimated 27.4% (95%CI: 22.8%-32.0%) or 1.8 million adults (95%CI: 1.6-2.1 million) had SARS-CoV-2 infection. SARS-CoV-2 prevalence was high among groups that are more vulnerable to severe SARS-CoV-2 and death, including unvaccinated persons (21.7%, 95%CI 9.6%-33.8%) and those aged 65+ (17.8%, 95%CI 10.2-25.4%). Population-based representative surveys are an important adjunct surveillance tool to standard testing-based SARS-CoV-2 surveillance.","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"72 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85548093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Huyen Nguyen, B. Hampel, David Garcia Nuñez, M. Battegay, A. Hachfeld, E. Bernasconi, A. Calmy, M. Cavassini, P. Vernazza, J. Fellay, Hannes Rudolph, M. Huber, K. Leuzinger, M. Perreau, A. Scherrer, A. Ramette, S. Yerly, H. Günthard, R. Kouyos, K. Kusejko
{"title":"Correction to: Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group.","authors":"Huyen Nguyen, B. Hampel, David Garcia Nuñez, M. Battegay, A. Hachfeld, E. Bernasconi, A. Calmy, M. Cavassini, P. Vernazza, J. Fellay, Hannes Rudolph, M. Huber, K. Leuzinger, M. Perreau, A. Scherrer, A. Ramette, S. Yerly, H. Günthard, R. Kouyos, K. Kusejko","doi":"10.1093/cid/ciac242","DOIUrl":"https://doi.org/10.1093/cid/ciac242","url":null,"abstract":"","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"81 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74705128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Chow, C. Fairley, H. Zou, Rebecca Wigan, S. Garland, A. Cornall, Steph Atchison, S. Tabrizi, Marcus Y. Chen
{"title":"Correction to: Human Papillomavirus Antibody Levels Following Vaccination or Natural Infection Among Young Men Who Have Sex With Men.","authors":"E. Chow, C. Fairley, H. Zou, Rebecca Wigan, S. Garland, A. Cornall, Steph Atchison, S. Tabrizi, Marcus Y. Chen","doi":"10.1093/cid/ciac245","DOIUrl":"https://doi.org/10.1093/cid/ciac245","url":null,"abstract":"","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"181 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80246766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Govender, A. Karat, S. Olivier, K. Baisley, Peter G. Beckwith, N. Dayi, J. Dreyer, D. Gareta, R. Gunda, K. Kielmann, O. Koole, N. Mhlongo, Tshwaraganang H Modise, S. Moodley, Xolile Mpofana, T. Ndung’u, D. Pillay, M. Siedner, T. Smit, Ashmika Surujdeen, E. Wong, A. Grant
{"title":"Correction to: Prevalence of Mycobacterium tuberculosis in Sputum and Reported Symptoms Among Clinic Attendees Compared With a Community Survey in Rural South Africa","authors":"I. Govender, A. Karat, S. Olivier, K. Baisley, Peter G. Beckwith, N. Dayi, J. Dreyer, D. Gareta, R. Gunda, K. Kielmann, O. Koole, N. Mhlongo, Tshwaraganang H Modise, S. Moodley, Xolile Mpofana, T. Ndung’u, D. Pillay, M. Siedner, T. Smit, Ashmika Surujdeen, E. Wong, A. Grant","doi":"10.1093/cid/ciac244","DOIUrl":"https://doi.org/10.1093/cid/ciac244","url":null,"abstract":"","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"10 1","pages":"363 - 363"},"PeriodicalIF":0.0,"publicationDate":"2022-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84178742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Makhtar Niang, M. Sandfort, Adja Fatou Mbodj, B. Diouf, C. Talla, J. Faye, Rokhaya Sané, L. Thiam, A. Thiam, A. Badiane, I. Vigan-Womas, N. Diagne, Fatoumata Diène Sarr, I. Mueller, C. Sokhna, M. White, Aissatou Toure-Balde
{"title":"Correction to: Fine-scale Spatiotemporal Mapping of Asymptomatic and Clinical Plasmodium falciparum Infections: Epidemiological Evidence for Targeted Malaria Elimination Interventions","authors":"Makhtar Niang, M. Sandfort, Adja Fatou Mbodj, B. Diouf, C. Talla, J. Faye, Rokhaya Sané, L. Thiam, A. Thiam, A. Badiane, I. Vigan-Womas, N. Diagne, Fatoumata Diène Sarr, I. Mueller, C. Sokhna, M. White, Aissatou Toure-Balde","doi":"10.1093/cid/ciac146","DOIUrl":"https://doi.org/10.1093/cid/ciac146","url":null,"abstract":"","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"32 1","pages":"2266 - 2267"},"PeriodicalIF":0.0,"publicationDate":"2022-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81335149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Benfield, J. Bodilsen, C. Brieghel, Z. Harboe, M. Helleberg, C. Holm, S. Israelsen, Janne Jensen, T. Jensen, I. Johansen, S. Johnsen, B. L. Madsen, J. Lundgren, C. Meyer, R. Mohey, L. Pedersen, H. Nielsen, S. L. Nielsen, N. Obel, L. Omland, D. Podlekareva, B. Poulsen, P. Ravn, H. Sandholdt, Jonathan Starling, M. Storgaard, C. Søborg, O. Søgaard, Torben Tranborg, L. Wiese, H. R. Christensen
{"title":"Correction to: Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study","authors":"T. Benfield, J. Bodilsen, C. Brieghel, Z. Harboe, M. Helleberg, C. Holm, S. Israelsen, Janne Jensen, T. Jensen, I. Johansen, S. Johnsen, B. L. Madsen, J. Lundgren, C. Meyer, R. Mohey, L. Pedersen, H. Nielsen, S. L. Nielsen, N. Obel, L. Omland, D. Podlekareva, B. Poulsen, P. Ravn, H. Sandholdt, Jonathan Starling, M. Storgaard, C. Søborg, O. Søgaard, Torben Tranborg, L. Wiese, H. R. Christensen","doi":"10.1093/cid/ciac243","DOIUrl":"https://doi.org/10.1093/cid/ciac243","url":null,"abstract":"","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"64 1","pages":"1889 - 1889"},"PeriodicalIF":0.0,"publicationDate":"2022-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90339563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. P. Cegielski, Z. Udwadia, P. Viiklepp, J. Yim, D. Menzies
{"title":"Correction to: Reply to van Deun and Decroo.","authors":"J. P. Cegielski, Z. Udwadia, P. Viiklepp, J. Yim, D. Menzies","doi":"10.1093/cid/ciac241","DOIUrl":"https://doi.org/10.1093/cid/ciac241","url":null,"abstract":"","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73639161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-22DOI: 10.1101/2022.04.21.22274155
N. Kojima, J. Klausner
We surveyed people that recently tested positive for SARS-CoV-2 to assess the frequency and correlates of early treatment seeking behavior. Among high risk respondents, 66.0% were aware of treatment for COVID-19 and 36.3% had sought treatment, however only 1.7% reported use of an antiviral for SARS-CoV-2 infection. More public outreach is needed to raise awareness of the benefits of treatment for COVID-19.
{"title":"Usage and awareness of antiviral medications for COVID-19","authors":"N. Kojima, J. Klausner","doi":"10.1101/2022.04.21.22274155","DOIUrl":"https://doi.org/10.1101/2022.04.21.22274155","url":null,"abstract":"We surveyed people that recently tested positive for SARS-CoV-2 to assess the frequency and correlates of early treatment seeking behavior. Among high risk respondents, 66.0% were aware of treatment for COVID-19 and 36.3% had sought treatment, however only 1.7% reported use of an antiviral for SARS-CoV-2 infection. More public outreach is needed to raise awareness of the benefits of treatment for COVID-19.","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"13 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91483453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Beldman, C. Löwik, Á. Soriano, Laila Albiach, W. Zijlstra, B. Knobben, P. Jutte, R. Sousa, A. Carvalho, K. Goswami, J. Parvizi, K. Belden, M. Wouthuyzen-Bakker
{"title":"Correction to: If, When, and How to Use Rifampin in Acute Staphylococcal Periprosthetic Joint Infections, a Multicentre Observational Study","authors":"M. Beldman, C. Löwik, Á. Soriano, Laila Albiach, W. Zijlstra, B. Knobben, P. Jutte, R. Sousa, A. Carvalho, K. Goswami, J. Parvizi, K. Belden, M. Wouthuyzen-Bakker","doi":"10.1093/cid/ciac149","DOIUrl":"https://doi.org/10.1093/cid/ciac149","url":null,"abstract":"","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"226 1","pages":"1890 - 1890"},"PeriodicalIF":0.0,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80139878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：